Joel Sendek Quotes
While our macro view is bullish on small-cap biotech for 2006, we do not recommend indiscriminate buying. 
Tweet
Macro | View | Bullish | Small | Biotech |
comments powered by Disqus
The company came through with about 38% operating margins this quarter, guiding 42% over the next couple of year. That's dramatic translation of top-line revenues to the bottom line.
- Joel Sendek
